Shots:

• The P-III KATHERINE study assessed Kadcyla vs Herceptin (trastuzumab) as an adjuvant therapy for patients with HER2-positive eBC for three years
• P-III KATHERINE study results: risk of disease recurrence or death 50%; didn’t have breast cancer return (88.3% vs 77.0%); with no new safety issues
• Kadcyla is an antibody-drug conjugate (ADC) developed for delivering CT directly to HER2-positive cancer cells and is approved in 104 countries including the US and EU for HER2-positive metastatic breast cancer

Ref: Roche | Image: Roche